BioStem Technologies, Inc. Common Stock · XNAS · 38 sessions on record
$3.09▼ −0.74 · −19.3%from $3.83 the session before · Sep 30, 2026 close · end of day
Open
$3.80
High
$3.84
Low
$3.00
Day's range
$0.8422% of the previous close
VWAP
$3.27close −5.4% from it
Volume, shares
333K1.90× the 20-session average
Traded, $
$1.1M
Trades
1.62K210 shares per trade
Previous close
$3.83−0.74 to the close
Market cap
$55.2Mat the close of Sep 30
Day range11% of the way up
$3.00$3.84
52-week range26% of the way up
$2.25 Aug 13$5.44 Sep 18
−43% from the high · +37% from the low
Options
No listed options on BSEM
Close $ · S&P 500 rebased to the first close38 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it
38 sessions on file · from Aug 7
BSEM close
S&P 500, rebased
Session read · latest close
Sep 30, 2026
Close $ · day %
$3.09▼ −19.3% on the previous close
Against S&P 500
S&P 500 −0.2%−19.1 pp difference on the day
Against the averages
below 2020-session $4.01 (−23%)
Volume
1.90×the previous 20 sessions · 333K shares
Extremes on the day
none
Quarterly results
consolidated · latest filed Aug 12, 2026 · SEC filings
Revenue $7.9M, −28% on a year earlier; profit −$9.0M, −85,000% in the Jun 2026 quarter, consolidated.
Last 2 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of BSEM on the consolidated basis with the market's move on the first session after each filing
Quarter
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
Market on the day
Jun 2026filed Aug 12
$7.9M
▼ −28%
−$9.0M
▼ −85,000%
-0.52
▼ −18.4%S&P 500 +0.7% · −19.1 pp
Jun 2025filed Aug 12
$11.0M
—
$10.6K
—
0.00
▼ −18.4%S&P 500 +0.7% · −19.1 pp
Fundamentals
consolidated · filings to Jun 2026 · close $3.09 on Sep 30
2.0 times book value, market cap $55.2M.
Valuation
Market cap
$55.2Mon Sep 30
Price to earnings
—
Trailing EPS
—
Price to book
2.0consolidated · balance sheet to Jun 2026
Book value a share
$1.55consolidated · balance sheet to Jun 2026
Debt to equity
0.00borrowings over equity · consolidated · balance sheet to Jun 2026
Return on equity
—
Dividend yield
—
Price to sales
—
Shares outstanding
17.8Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—
Profit, trailing 12 months
—
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersBiological Products, (No Diagnostic Substances) · the ten largest by market cap · industry P/E needs two stocks with trailing profit and a market cap
Stocks in the industry Biological Products, (No Diagnostic Substances) with market cap, price to earnings and price to book
Biological Products, (No Diagnostic Substances) · SEC standard industrial classification
SEC CIK
1658678
Sessions on record
38
Price source
End of day · delayed
Computed
1 Oct, 08:19 pm IST
OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.